Literature DB >> 35053624

Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681.

Marwan Kwok1,2, Angelo Agathanggelou1, Nicholas Davies1, Tatjana Stankovic1.   

Abstract

The authors wish to make the following corrections to their paper [1] [...].

Entities:  

Year:  2022        PMID: 35053624      PMCID: PMC8774224          DOI: 10.3390/cancers14020321

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


The authors wish to make the following corrections to their paper [1]: There was an error in the original publication. Page 3. “Monoallelic TP53 aberrations exert a more detrimental prognostic impact, compared to biallelic alterations.” This is incorrect. It should read: “Monoallelic TP53 alterations exert a less detrimental prognostic impact, compared to biallelic alterations.” There was an error in the original publication. Page 13. “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [2].” Reference [2] was erroneously cited. The correct reference here should be reference [1]. This sentence should read: “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [1].” There was an error in the original publication. Page 14. “in combination with existing immunomodulatory agents such as the PD-1/PD-L1 inhibitors lenalidomide and ibrutinib” This sentence should read in “in combination with existing immunomodulatory agents such as PD-1/PD-L1 inhibitors, lenalidomide and ibrutinib.” In the original publication, there was a mistake in Table 1: “Döhner” was misspelt as “Doner”. The corrected Table 1 appears below.
Table 1

Frequency of different p53 pathway alterations in patients with chronic lymphocytic leukemia.

GeneMutation FrequencyDeletion FrequencyNumber of Patients AnalyzedReference
ATM ND18%325Döhner et al., 2000 [17]
32%4%50Stankovic et al., 2002 [13]
12%3%155Austen et al., 2005 [14]
ND22%330Malcikova et al., 2009 [15]
14.7%30%224Skowronska et al., 2012 [19]
8%15%160Landau et al., 2013 [25]
15%22%538Landau et al., 2015 [26]
TP53 ND7%325Döhner et al., 2000 [17]
12%6%50Stankovic et al., 2002 [13]
4%ND155Austen et al., 2005 [14]
5%11%400Malcikova et al., 2009 [15]
8.5%5%328Zenz et al., 2010 [16]
7.6%6%529Gonzalez et al., 2011 [27]
15%ND309Rossi et al., 2014 [28]
11.5%7%635Stilgenbauer et al., 2014 [29]
13%13%160Landau et al., 2013 [25]
7%6.3%538Landau et al., 2015 [26]

Abbreviations: ND, not determined.

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.
  1 in total

Review 1.  Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives.

Authors:  Marwan Kwok; Angelo Agathanggelou; Nicholas Davies; Tatjana Stankovic
Journal:  Cancers (Basel)       Date:  2021-09-18       Impact factor: 6.639

  1 in total
  3 in total

1.  Dispirooxindole-β-Lactams: Synthesis via Staudinger Ketene-Imine Cycloaddition and Biological Evaluation.

Authors:  Vadim E Filatov; Dmitrii A Iuzabchuk; Viktor A Tafeenko; Yuri K Grishin; Vitaly A Roznyatovsky; Dmitrii A Lukianov; Yulia A Fedotova; Maxim A Sukonnikov; Dmitry A Skvortsov; Nikolai V Zyk; Elena K Beloglazkina
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

2.  Sulfurtransferases and Cystathionine Beta-Synthase Expression in Different Human Leukemia Cell Lines.

Authors:  Halina Jurkowska; Maria Wróbel; Ewa Jasek-Gajda; Leszek Rydz
Journal:  Biomolecules       Date:  2022-01-18

3.  ATM Pathway Is Essential for HPV-Positive Human Cervical Cancer-Derived Cell Lines Viability and Proliferation.

Authors:  Walason Abjaude; Bruna Prati; Veridiana Munford; Aline Montenegro; Vanesca Lino; Suellen Herbster; Tatiana Rabachini; Lara Termini; Carlos Frederico Martins Menck; Enrique Boccardo
Journal:  Pathogens       Date:  2022-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.